Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer
Inclusion Criteria:
- Histologically or cytologically proven inoperable stage IIIb-IV NSCLC
- ECOG PS 0-1
- Life expectancy > 3 months
- Adequate blood functions: Absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelet
count ≥ 100 x 109/L, and hemoglobin ≥ 9 g / dL
- Adequate liver function: total bilirubin <1.5 times the upper limit of normal (ULN);
AST and ALT <2.5 times ULN in patients without liver metastases, <5 times ULN in
patients with liver metastases
- Adequate renal function: serum creatinine ≤ 1.25 times ULN or calculated creatinine
clearance ≥ 50 mL / min and urinary protein <2+. In patients with baseline urinary
protein ≥ 2+, 24 hours urine should be collected and 24 hours urine protein ≤ 1g
- International normalized ratio (INR) ≤ 1.5 and prothrombin time(PT) ≤ 1.5 times ULN
within 7 days before enrollment
- Written informed consent
Exclusion Criteria:
- Evidence of bleeding diathesis or coagulopathy
- History of hemoptysis, defined as bright red blood more than half a teaspoon 3 months
before enrollment
- Previously received chemotherapy and radiotherapy and biological targeted therapy
- Uncontrolled hypertension (systolic blood pressure> 150 mmHg and/or diastolic blood
pressure> 100 mm Hg)
- Clinically significant (ie, active) cardiovascular diseases, such as cerebrovascular
accident (within 6 months before initiating treatment), myocardial infarction (within
6 months before initiating treatment), unstable angina, congestive heart failure (New
York Heart Association class ≥Grade II) , serious arrhythmia which needs medication
during the study and may affect the study or can not be controlled by drugs
- Unhealed wounds, active peptic ulcer or fracture
- Gastrointestinal fistula, gastrointestinal perforation or intra-abdominal abscess
within 6 months before enrollment
- Women with intact uterus (menopause more than two years excluded) who are unwilling
to take effective non-hormonal contraception (IUD, spermicide barrier birth control
device or sterilization) during the study. Male who are unwilling to take effective
contraceptive measures during the study
- Participated in other clinical trials within 28 days before the initiation of
treatment.
- Allergic to any of the study drugs